Cullen Investment Group LTD. Buys 267 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Cullen Investment Group LTD. boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,575 shares of the medical research company’s stock after buying an additional 267 shares during the period. Cullen Investment Group LTD.’s holdings in IQVIA were worth $4,043,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Pallas Capital Advisors LLC bought a new position in IQVIA during the 4th quarter worth approximately $298,000. Claro Advisors LLC bought a new stake in shares of IQVIA during the fourth quarter valued at about $281,000. Czech National Bank increased its position in shares of IQVIA by 6.0% in the fourth quarter. Czech National Bank now owns 37,386 shares of the medical research company’s stock worth $7,347,000 after purchasing an additional 2,107 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of IQVIA by 1.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after purchasing an additional 56 shares during the period. Finally, Nordea Investment Management AB boosted its stake in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

IQVIA stock opened at $204.50 on Tuesday. The firm has a 50-day moving average price of $201.73 and a 200-day moving average price of $221.71. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm has a market capitalization of $37.12 billion, a PE ratio of 26.84, a price-to-earnings-growth ratio of 2.05 and a beta of 1.48.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IQV. Robert W. Baird lowered their price target on IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Leerink Partners restated an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Truist Financial decreased their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Wednesday, December 11th. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $255.82.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.